Literature DB >> 11707965

[Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers].

M Maruyama1, Y Toukairin, H Baba, N Kure, T Nagahama, M Ebuchi.   

Abstract

We studied the pharmacokinetics of the intraperitoneal administration of CPT-11 for four patients with peritoneal metastasis (2 gastric cancer cases, 2 colon cancer cases). CPT-11 was administrated in a dose of 40-60 mg and the intraperitoneal and serum levels of CPT-11, SN-38 and SN-38 glucuronized (SN-38 Glu) were measured periodically. Intraperitoneal therapy with CPT-11 was effective for the control of malignant ascites. No serious side effects were observed. The levels of CPT-11, SN-38 were no different 30 min afterwards the administration of CPT-11 either intraperitoneally or intravenously. The high concentration of CPT-11 was achieved with intraperitoneal therapy and a small fraction of CPT-11 changed into SN-38 in the abdominal cavity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11707965

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

1.  Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration.

Authors:  Byung-Jin Ahn; Moon Ki Choi; Young Suk Park; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Ho Yeong Lim; Won Ki Kang; Jae-Wook Ko; Dong-Seok Yim
Journal:  Eur J Clin Pharmacol       Date:  2010-09-09       Impact factor: 2.953

Review 2.  A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer.

Authors:  Fadi Sami Farhat
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

3.  Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.

Authors:  Nadine Leonie de Boer; Alexandra R M Brandt-Kerkhof; Eva V E Madsen; Marjolein Diepeveen; Esther van Meerten; Ruben A G van Eerden; Femke M de Man; Rachida Bouamar; Stijn L W Koolen; Ignace H J T de Hingh; Checca Bakkers; Koen P Rovers; Geert-Jan M Creemers; Maarten J Deenen; Onno W Kranenburg; Alexander Constantinides; Ron H J Mathijssen; Cornelis Verhoef; Jacobus W A Burger
Journal:  BMJ Open       Date:  2019-12-08       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.